• Addition of CRO Builds Cancer Model Network Support
    Fiona Nielson

News & Views

Addition of CRO Builds Cancer Model Network Support

Pharmatest, a contract research organisation providing clinically predictive preclinical efficacy services for oncology and skeletal diseases, has joined the global network of Repositive’s directory of preclinical cancer models.

“At Repositive, we are committed to establishing new partnerships with specialist CROs to further enhance and strengthen our world-class offering of preclinical cancer models to biopharmaceutical researchers worldwide," said Fiona Nielsen, CEO of Repositive. "Our collaboration with Pharmatest will enable us to do just that,” she added.

"We chose to partner with Repositive because of their ground-breaking, compelling platform, which helps to connect key players in the preclinical cancer research field," said Dr Jukka Rissanen, CEO of Pharmatest. "At Pharmatest, we have unique expertise in the field of bone metastases that we want to be able to share as widely as possible and collaborating with Repositive seems like a great way to do this."


Digital Edition

LMUK 49.7 Nov 2024

November 2024

News - Research & Events News   - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...

View all digital editions

Events

analytica China

Nov 18 2024 Shanghai, China

Pharma Asia

Nov 20 2024 Karachi, Pakistan

Turkchem

Nov 27 2024 Istanbul, Turkey

Smart Factory Expo 2025

Jan 22 2025 Tokyo, Japan

Instrumentation Live

Jan 22 2025 Birmingham, UK

View all events